To explore the mechanism behind CTNNB1-MUT and poor immunotherapy response in HCC patients we focused on immune cells, expression of immune-related molecules, and immune related signatures, as the TIME has been shown to play an important role. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.